Exhibit 99.2
+ Erik Holmlin, PhD, CEO of Bionano GenomicsAugust 24, 2020 Creating a leader in digital cytogenetics through a combination of systems & consumables with Laboratory Developed Tests (LDTs) & services in a CLIA-certified setting

Legal Disclaimer This presentation contains forward-looking statements. Forward-looking statements describe future expectations, plans, results or strategies and are generally preceded by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential” and similar expressions (including the negative thereof). Forward-looking statements in this presentation include, but are not limited to, statements regarding: (i) growth drivers and expected levels of our organic growth; (ii) synergies created by our acquisition of Lineagen; (iii) the impact of our investment in R&D and commercial initiatives; (iv) our ability to stay in front of competitors’ improvements in technologies; (v) other statements that are not historical facts. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Forward-looking statements are based only on current information, assumptions and expectations, and involve a number of risks and uncertainties relating to (i) challenges inherent in developing, manufacturing and commercializing products; (ii) the timing and mix of customer orders among our products; (iii) our ability to further deploy new products and applications and expand the markets for our technology platforms; (iv) third parties’ abilities to manufacture our instruments and consumables; (v) the success of products competitive with our own; (vi) our expectations and beliefs regarding future growth of the combined business and the markets in which we operate; (vii) the accuracy of our estimates, (viii) our ability to fund our operations and (ix) the application of generally accepted accounting principles which are highly complex and involve many subjective assumptions. We are under no duty to update any of these forward-looking statements after the date of this presentation to conform these statements to actual results or revised expectations, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this presentation. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements contained in this presentation. More information about these and other statements, risks and uncertainties is contained in our filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this presentation speak only as of the date on which they were made. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, occurrence of future events or otherwise except as required by applicable law.

Bionano Sells the Saphyr System to Detect the Other Genome Variant: Structural Variations (SVs)

Uses combination of multiple techniques incl. microscopes to manually visualize banding patterns on intact chromosomes to detect SVs Saphyr May Drive the Digital Cytogenetics Revolution Uses Saphyr to automatically image 1000x more label patterns on single DNA molecules in massively parallel nanochannels to detect SVs CYTOGENETICS DIGITAL CYTOGENETICS Cytogenetic & chromosomal SV analysis is FIRST LINE analysis in guidelines by NCCN, WHO, ACMG, etc. for genetic diseases, liquid tumors (leukemias and lymphomas), and solid tumors (cancer) KARYOTYPINGMax resolution of ~5MbRequires cell culture FISHOnly tests selected genesLow throughput MICROARRAYOnly detects deletions and duplications, misses all balanced events

Lineagen is a Complementary Business that Provides Actionable Information through Diagnostic Services to Patients with Developmental Disorders FROM ONE BUCCAL SWAB . . . Five tests providing multiple revenue streamsCLIA-certified LDTs and servicesPersonalized, easy-to-understand resultsGenetic counseling and clinical educationEnd-to-end support with reimbursement

More than Products: Lineagen is an Accelerant for Digital Cytogenetics ESSENTIAL COMPONENTS FOR BUILDING REIMBURSED DX MENU ON SAPHYR Trained billing specialists lay groundwork for reimbursement of Saphyr LDTs COMBINING PRODUCT-AND SERVICE-BASED BUSINESSES Proprietary database from Toronto Sick Kids Hospital provides basis for differentiated tests, current and future +60,000 tests performed on +30,000 patients, and counting Proprietary Content in Pediatric Neuro Developmental Disorders Patient Samples & Database Provide expertise for improved Saphyr Dx and workflow integration Differentiated service and critical link between physicians, patients and families Leverage existing relationships and contracts with payors Clinical Cytogeneticists & Custom Interpretation Software Genetic Counseling Certified Coders 3rd Party Payor Contracts REVENUE: IMMEDIATE IMPACT Lineagen adds new revenue streams to help support growth of the combined business Provides centralized and decentralized offerings to support the broader market Development of proprietary LDTs helps drive Saphyr adoptionEnhances Bionano offering to pharma customers seeking new therapeutic targets CLIA Certification Accelerates Saphyr entry into the clinic by adding content, skills, expertise and sample archives

Saphyr genome imaging system and consumables sold to leading scientists and clinicians for digital cytogeneticsAddresses a $2.6-3.8B market opportunity with system placement opportunity of ~10,000 systemsAdoption by leading cytogenetics labs in US and EuropeGrowing bibliography of publications validate Saphyr as replacement for traditional cytogenetic methods including karyotyping, FISH and CMA, plus outdated molecular methods such as Southern Blot. They underscore Saphyr’s ability to find SVs other methods fail to detect101 employeesLTM Revenues (June 30, 2020) $8.5 million Bionano + Lineagen Side-by-Side:Critical Mass to Support Global Adoption of Saphyr and Address Significant Clinical Unmet Needs Bionano GenomicsProducts: Systems, consumables and software for highly accurate structural variation analysis A leader in digital cytogenetics providing researchers and clinicians with the tools to detect structural variations Portfolio of CLIA-certified Laboratory Developed Tests to assist physicians in diagnosing genetic conditions sooner to develop personalized healthcare management for patients and familiesAddresses a $1B market for pediatric development disorders Proprietary content and powerful reports supported by robust team of clinical genetic specialists, including genetic counselors and cytogeneticists Strong commercial organization with extensive capabilities in the USMulti-year history of contracted, reliable & stable reimbursement from prominent public and private payors35 employeesLTM Revenues (June 30, 2020) $6.0 million LineagenServices: Laboratory Developed Tests through CLIA-certified services for pediatric genetic disorders A leader in neurodevelopmental disorder testing with CLIA-certified LDTs for both pediatric specialists and generalists alike

Bionano + Lineagen As One:Topline Expansion, Bigger Addressable Market, Deeper Market Penetration & New Products as Bionano Expands Clinical Applications MULTIPLE WAYS TO ACCELERATE CLINICAL ADOPTION Existing Bionano Business Existing Lineagen Business First-Line CMA tests + WES + Expand to more services, including pharma services with Partner Labs Leverage Lineagen’s reimbursement expertise to sell more Saphyrs Novel Laboratory developed tests (LDTs) Potential FDA-cleared tests + + + +

The Combination Drives Financial Benefits REVENUE SYNERGIES Rapid market expansion for Saphyr Expand Lineagen testing to new markets Proprietary Cytogenetics IVD development Operating Expenses Lineagen provides BNGO with a strategic platform in the form of CLIA-certification and an existing commercial channel to support Saphyr adoption in new markets Today Lineagen’s cytogenetic testing capabilities are focused on the pediatric neurodevelopmental market leaving many other markets, such as cancer, ripe for expansion Together, BNGO and Lineagen are in an excellent position to develop high-performing/high-margin clinical diagnostics that can be first commercialized in the lab and ultimately as IVDs Leveraging multiple economies of scale for combined companies COST SYNERGIES

Combining A Genomics Platform Company With A Diagnostic Testing Company Has Been Done Before 2013 2020 + Illumina Verinata Health Invitae Archer +

2019 Pro Forma Financial Snapshot ($ in millions) Revenue Cost of Revenue LineagenStandalone BNGOStandalone $10.1M $6.8M $7.5M $3.4M BNGO+LineagenPro forma $17.6M $10.2M 2019

Summary Terms ($ in millions) Bionano acquired Lineagen by way of a stock deal valued at approximately$9.6M plus repayment of Lineagen’s $1.1M PPP loan Consideration Cash: None Stock: ~6.2M (based on pps of $0.81) $5M Shares: Value: Liabilities: $4.6M in trade payables assumed1 + $1.1M PPP loan repayment $9.6 M + $1.1M PPP loan repayment Total Consideration: Earnout: None 1 Approximately $1.7 million in liabilities were paid in full at closing (in addition to repayment of Lineagen’s PPP loan)

Creating a leader in digital cytogenetics through a combination of systems & consumables with Laboratory Developed Tests (LDTs) & services in a CLIA-certified setting + Erik Holmlin, PhD, CEO of Bionano GenomicsAugust 24, 2020